Ionis Pharmaceuticals Inc. IONS
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in Ionis Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.
Growth
Revenue compounded at +5.3% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 71 cents this year.
The 18-year record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.9 | 0.7 | 0.8 | 0.6 | 0.8 | 0.7 | 1.1 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Operating income $B | −0.4 | −0.5 | −0.4 | −0.4 | −0.0 | −0.2 | 0.4 | −0.1 | 0.0 | −0.0 | −0.1 | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.4 | −0.5 | −0.3 | −0.4 | −0.0 | −0.2 | 0.4 | −0.1 | 0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | −0.0 | 0.0 | 0.0 | −0.0 | 0.3 | 0.1 | −0.3 | −0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | ◌ |
| Net income $B | −0.4 | −0.5 | −0.4 | −0.3 | −0.0 | −0.4 | 0.3 | 0.3 | 0.0 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | 0.2 | −0.0 |
| Free cash flow $B | −0.3 | −0.5 | −0.3 | −0.3 | 0.0 | 0.0 | 0.3 | 0.6 | 0.1 | −0.1 | 0.0 | −0.0 | 0.1 | 0.0 | −0.1 | −0.1 | −0.1 | 0.2 |
| EPS, diluted $ | −2.38 | −3.04 | −2.56 | −1.90 | −0.20 | −3.18 | 1.90 | 2.07 | 0.15 | −0.50 | −0.74 | −0.33 | −0.55 | −0.65 | −0.85 | −0.62 | 1.58 | −0.19 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −70.8 | −93.1 | −76.3 | −40.1 | −3.8 | −40.1 | 22.1 | 41.2 | 0.2 | −40.2 | −38.5 | −12.3 | −21.6 | ◌ | ◌ | −22.8 | 70.6 | −12.3 |
| Shares out B | 0.16 | 0.16 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.10 | 0.10 | 0.10 | 0.10 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 18 of the 18 fiscal years we could check. Nine checks were skipped: cost of revenue is not tagged before 2016. Four checks were skipped: the balance sheet is not tagged before 2009. One check was skipped: EPS is not tagged before 2008.